person · Reporting owner

Ellingson Rachel

Disclosed activity across 3 companies

Tapewire entity: 64609
SEC CIK: 0001557271

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278	Chief Administrative Officer	February 20, 2025	February 24, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ZIMMER BIOMET HOLDINGS, INC.

Report date February 20, 2025 · Filed February 24, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,906	Ending reported balance After 2025-02-20 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2025-02-20 · Exercise / conversion · Acquired 1,566 · Balance 12,397 Row 2 · 2025-02-20 · Tax withholding · Disposed 491 · Balance 11,906 F1: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs").
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	3,131	Reported balance After 2025-02-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-02-20 · Exercise / conversion · Disposed 1,566 · Balance 3,131 F2: Each RSU represents a contingent right to receive one share of Company common stock. F3: One-third of the RSUs vested on February 20, 2025. The remaining RSUs vest one-half on each of February 20, 2026 and February 20, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs").

F2: Each RSU represents a contingent right to receive one share of Company common stock.

F3: One-third of the RSUs vested on February 20, 2025. The remaining RSUs vest one-half on each of February 20, 2026 and February 20, 2027.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

BIOLIFE SOLUTIONS INC

Report date October 06, 2026 · Filed October 09, 2026

Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2026-10-06 transaction · row 1 1 source row Row 1 · 2026-10-06 · Disposition to issuer · Disposed 57,995 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.

ST JUDE MEDICAL, LLC

Report date January 04, 2017 · Filed January 06, 2017

Section 16 reporting ended · disclosed 2017-01-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-01-04 transaction · row 1 1 source row Row 1 · 2017-01-04 · Disposition to issuer · Disposed 8,732 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.96 · Expires 2019-12-12	Direct	Reported balance After 2017-01-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-01-04 · Disposition to issuer · Disposed 1,383 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.27 · Expires 2020-12-10	Direct	Reported balance After 2017-01-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-01-04 · Disposition to issuer · Disposed 14,749 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.41 · Expires 2021-12-10	Direct	Reported balance After 2017-01-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-01-04 · Disposition to issuer · Disposed 13,380 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.08 · Expires 2022-12-08	Direct	Reported balance After 2017-01-04 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-01-04 · Disposition to issuer · Disposed 19,616 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.62 · Expires 2023-12-07	Direct	Reported balance After 2017-01-04 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2017-01-04 · Disposition to issuer · Disposed 25,464 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2017-01-04 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-01-04 · Disposition to issuer · Disposed 401 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2017-01-04 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2017-01-04 · Disposition to issuer · Disposed 1,114 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2017-01-04 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2017-01-04 · Disposition to issuer · Disposed 2,028 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.

F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.

F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.

F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 06, 2026 Filed Oct 9, 2026 01:59 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	Disposition to issuerCommon Stock	57,995	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-418327 · ownership.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. Read SEC document
February 24, 2026 Filed Feb 26, 2026 22:55 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	GrantCommon Stock	8,170	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-26-012476 · wk-form4_1772146544.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,995 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan and fully vests on the first anniversary of the vesting date of January 2, 2026 Read SEC document
March 18, 2025 Filed Mar 20, 2025 23:08 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	GrantCommon Stock	6,876	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-25-014186 · wk-form4_1742512108.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,825 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the measurement date of 01-02-2025. Read SEC document
February 20, 2025 Filed Feb 24, 2025 21:11 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionRestricted Stock Units · Derivative	1,566	$0.00	$0.00	Disclosure SEC source: 0001062993-25-003344 · form4.xml · derivative · entry 3 Ellingson Rachel · CIK 0001557271 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,131 Underlying: Common Stock · 1,566 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Company common stock. F3 · derivative.exercise_date: One-third of the RSUs vested on February 20, 2025. The remaining RSUs vest one-half on each of February 20, 2026 and February 20, 2027. F3 · derivative.expiration_date: One-third of the RSUs vested on February 20, 2025. The remaining RSUs vest one-half on each of February 20, 2026 and February 20, 2027. Read SEC document
February 20, 2025 Filed Feb 24, 2025 21:11 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Tax withholdingCommon Stock	491	$103.46	$50,798.86	Disclosure SEC source: 0001062993-25-003344 · form4.xml · nonDerivative · entry 2 Ellingson Rachel · CIK 0001557271 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,906 F1 · shares: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Read SEC document
February 20, 2025 Filed Feb 24, 2025 21:11 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionCommon Stock	1,566	$0.00	$0.00	Disclosure SEC source: 0001062993-25-003344 · form4.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,397 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 18, 2025 Filed Feb 19, 2025 22:56 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionRestricted Stock Units · Derivative	5,572	$0.00	$0.00	Disclosure SEC source: 0001062993-25-002910 · form4.xml · derivative · entry 4 Ellingson Rachel · CIK 0001557271 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,572 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Company common stock. Read SEC document
February 18, 2025 Filed Feb 19, 2025 22:56 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Tax withholdingCommon Stock	1,792	$101.00	$180,992.00	Disclosure SEC source: 0001062993-25-002910 · form4.xml · nonDerivative · entry 2 Ellingson Rachel · CIK 0001557271 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,831 F2 · shares: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Read SEC document
February 18, 2025 Filed Feb 19, 2025 22:56 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionCommon Stock	5,572	$0.00	$0.00	Disclosure SEC source: 0001062993-25-002910 · form4.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 205 shares acquired under the Employee Stock Purchase Plan through February 18, 2025. Read SEC document
February 14, 2025 Filed Feb 19, 2025 22:56 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	GrantRestricted Stock Units · Derivative	5,572	$0.00	$0.00	Disclosure SEC source: 0001062993-25-002910 · form4.xml · derivative · entry 3 Ellingson Rachel · CIK 0001557271 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,572 Underlying: Common Stock · 5,572 shares Expires 2025-02-18 F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Company common stock. F4 · shares: On February 18, 2022, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2022 - 2024. As determined on February 14, 2025, based on actual performance, the reporting person earned 5,572 RSUs, which vested on February 18, 2025. F4 · derivative.underlying_shares: On February 18, 2022, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2022 - 2024. As determined on February 14, 2025, based on actual performance, the reporting person earned 5,572 RSUs, which vested on February 18, 2025. Read SEC document
March 08, 2024 Filed Mar 13, 2024 01:44 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	GrantCommon Stock	11,264	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-24-010751 · wk-form4_1710294284.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,949 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the grant date. Read SEC document
March 06, 2024 Filed Mar 8, 2024 22:03 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionRestricted Stock Units · Derivative	1,419	$0.00	$0.00	Disclosure SEC source: 0001062993-24-006022 · form4.xml · derivative · entry 3 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,837 Underlying: Common Stock · 1,419 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F3 · derivative.exercise_date: One-third of the RSUs vested on March 6, 2024. The remaining RSUs vest one-half on each of March 6, 2025 and March 6, 2026. F3 · derivative.expiration_date: One-third of the RSUs vested on March 6, 2024. The remaining RSUs vest one-half on each of March 6, 2025 and March 6, 2026. Read SEC document
March 06, 2024 Filed Mar 8, 2024 22:03 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Tax withholdingCommon Stock	445	$125.82	$55,989.90	Disclosure SEC source: 0001062993-24-006022 · form4.xml · nonDerivative · entry 2 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,846 F1 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Read SEC document
March 06, 2024 Filed Mar 8, 2024 22:03 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionCommon Stock	1,419	$0.00	$0.00	Disclosure SEC source: 0001062993-24-006022 · form4.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 25, 2024 Filed Feb 28, 2024 01:57 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionRestricted Stock Units · Derivative	1,762	$0.00	$0.00	Disclosure SEC source: 0001062993-24-004687 · form4.xml · derivative · entry 3 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,762 shares Expires 2024-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Company common stock. F1 · shares: This number of restricted stock units ("RSUs") reflects the adjustments that occurred as of March 1, 2022 in connection with Zimmer Biomet Holdings, Inc.'s (the "Company") spinoff of Zimvie Inc. In connection with the spinoff, each RSU was adjusted to preserve the intrinsic value of such award by multiplying it by an equity exchange ratio, rounded up to the nearest whole unit, which adjustments were made following the initial reporting of these RSUs. Read SEC document
February 25, 2024 Filed Feb 28, 2024 01:57 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Tax withholdingCommon Stock	588	$128.80	$75,734.40	Disclosure SEC source: 0001062993-24-004687 · form4.xml · nonDerivative · entry 2 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,872 F3 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations on the vesting of RSUs. Read SEC document
February 25, 2024 Filed Feb 28, 2024 01:57 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionCommon Stock	1,762	$0.00	$0.00	Disclosure SEC source: 0001062993-24-004687 · form4.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This number of restricted stock units ("RSUs") reflects the adjustments that occurred as of March 1, 2022 in connection with Zimmer Biomet Holdings, Inc.'s (the "Company") spinoff of Zimvie Inc. In connection with the spinoff, each RSU was adjusted to preserve the intrinsic value of such award by multiplying it by an equity exchange ratio, rounded up to the nearest whole unit, which adjustments were made following the initial reporting of these RSUs. F2 · balance_after: Includes 195 shares acquired under the Company's Employee Stock Purchase Plan through February 1, 2024. Read SEC document
February 20, 2024 Filed Feb 23, 2024 01:59 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	GrantRestricted Stock Units · Derivative	4,697	$0.00	$0.00	Disclosure SEC source: 0001062993-24-004132 · form4.xml · derivative · entry 1 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,697 Underlying: Common Stock · 4,697 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F2 · derivative.exercise_date: Vests annually over three years in increments of one-third each year, commencing February 20, 2025. F2 · derivative.expiration_date: Vests annually over three years in increments of one-third each year, commencing February 20, 2025. Read SEC document
November 01, 2023 Filed Nov 3, 2023 21:10 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	GrantCommon Stock	495	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-23-036780 · wk-form4_1699045799.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,685 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash director fees at the last closing price as of the date of grant. Read SEC document
October 01, 2023 Filed Oct 10, 2023 21:26 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	GrantCommon Stock	362	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-23-034206 · wk-form4_1696973203.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,190 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash director fees at the last closing price as of the date of grant. Read SEC document
March 06, 2023 Filed Mar 8, 2023 21:25 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	GrantRestricted Stock Units · Derivative	4,256	$0.00	$0.00	Disclosure SEC source: 0001062993-23-006280 · form4.xml · derivative · entry 1 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,256 Underlying: Common Stock · 4,256 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F2 · derivative.exercise_date: Vests annually over three years in increments of one-third each year, commencing March 6, 2024. F2 · derivative.expiration_date: Vests annually over three years in increments of one-third each year, commencing March 6, 2024. Read SEC document
February 21, 2023 Filed Feb 23, 2023 22:52 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionRestricted Stock Units · Derivative	1,046	$0.00	$0.00	Disclosure SEC source: 0001062993-23-004623 · form4.xml · derivative · entry 3 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,046 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Company common stock. F1 · shares: This number of restricted stock units ("RSUs") reflects the adjustments that occurred as of March 1, 2022 in connection with Zimmer Biomet Holdings, Inc.'s (the "Company") spinoff of Zimvie Inc. In connection with the spinoff, each RSU was adjusted to preserve the intrinsic value of such award by multiplying it by an equity exchange ratio, rounded up to the nearest whole unit, which adjustments were made following the initial reporting of these RSUs. Read SEC document
February 21, 2023 Filed Feb 23, 2023 22:52 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Tax withholdingCommon Stock	361	$124.73	$45,027.53	Disclosure SEC source: 0001062993-23-004623 · form4.xml · nonDerivative · entry 2 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,503 F3 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations on the vesting of RSUs. Read SEC document
February 21, 2023 Filed Feb 23, 2023 22:52 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionCommon Stock	1,046	$0.00	$0.00	Disclosure SEC source: 0001062993-23-004623 · form4.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This number of restricted stock units ("RSUs") reflects the adjustments that occurred as of March 1, 2022 in connection with Zimmer Biomet Holdings, Inc.'s (the "Company") spinoff of Zimvie Inc. In connection with the spinoff, each RSU was adjusted to preserve the intrinsic value of such award by multiplying it by an equity exchange ratio, rounded up to the nearest whole unit, which adjustments were made following the initial reporting of these RSUs. F2 · balance_after: Includes 194 shares acquired under the Company's Employee Stock Purchase Plan on June 30, 2022. Read SEC document
January 03, 2023 Filed Jan 19, 2023 00:00 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	GrantCommon Stock	10,187	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-23-001264 · rdgdoc.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,828 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and fully vests on the first anniversary of the grant date. Read SEC document
August 01, 2022 Filed Aug 3, 2022 00:00 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	GrantCommon Stock	259	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-22-018511 · rdgdoc.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,641 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of directors fees at the last closing price as of the date of grant. Read SEC document
July 01, 2022 Filed Jul 7, 2022 00:01 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	GrantCommon Stock	341	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-22-016765 · rdgdoc.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,382 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of directors fees at the last closing price as of the date of grant. Read SEC document
June 01, 2022 Filed Jun 4, 2022 00:01 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	GrantCommon Stock	311	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-22-014307 · rdgdoc.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,041 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of directors fees at the last closing price as of the date of grant. Read SEC document
May 06, 2022 Filed May 11, 2022 00:01 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	GrantCommon Stock	14,730	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-22-011803 · rdgdoc.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,730 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and fully vests on the first anniversary of the grant date. Read SEC document
May 01, 2022 Filed May 3, 2022 20:41 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionRestricted Stock Units · Derivative	531	$0.00	$0.00	Disclosure SEC source: 0001062993-22-011409 · form4.xml · derivative · entry 3 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 531 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F4 · shares: Amount reflects the adjustments that occurred as of March 1, 2022 in connection with the Company's spinoff of ZimVie Inc. In connection with the spinoff, each outstanding RSU was adjusted to preserve the intrinsic value of such award by multiplying it by an equity exchange ratio, rounded up to the nearest whole unit. F5 · derivative.exercise_date: The remaining 531 RSUs vested on May 1, 2022. F5 · derivative.expiration_date: The remaining 531 RSUs vested on May 1, 2022. F4 · derivative.underlying_shares: Amount reflects the adjustments that occurred as of March 1, 2022 in connection with the Company's spinoff of ZimVie Inc. In connection with the spinoff, each outstanding RSU was adjusted to preserve the intrinsic value of such award by multiplying it by an equity exchange ratio, rounded up to the nearest whole unit. Read SEC document
May 01, 2022 Filed May 3, 2022 20:41 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Tax withholdingCommon Stock	167	$122.43	$20,445.81	Disclosure SEC source: 0001062993-22-011409 · form4.xml · nonDerivative · entry 2 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,624 F2 · shares: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Read SEC document
May 01, 2022 Filed May 3, 2022 20:41 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionCommon Stock	531	$0.00	$0.00	Disclosure SEC source: 0001062993-22-011409 · form4.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 162 shares acquired under the Zimmer Biomet Holdings, Inc. Employee Stock Purchase Plan on June 30, 2021 and December 31, 2021. Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:06 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	GrantRestricted Stock Units · Derivative	1,708	$0.00	$0.00	Disclosure SEC source: 0001062993-22-006629 · form4.xml · derivative · entry 2 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,708 Underlying: Common Stock · 1,708 shares Expires 2024-02-25 F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:06 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	GrantRestricted Stock Units · Derivative	1,014	$0.00	$0.00	Disclosure SEC source: 0001062993-22-006629 · form4.xml · derivative · entry 1 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,014 Underlying: Common Stock · 1,014 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F2 · shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. F2 · derivative.underlying_shares: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. F2 · balance_after: In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units ("PRSUs") held by Company employees, included the reporting person, were converted into time-based RSUs. Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level. The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed. Read SEC document
February 18, 2022 Filed Feb 23, 2022 22:05 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	GrantEmployee Stock Option (right to buy) · Derivative	12,891	$0.00 Strike: $120.82	$0.00	Disclosure SEC source: 0001062993-22-005364 · form4.xml · derivative · entry 1 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,891 Underlying: Common Stock · 12,891 shares Expires 2032-02-18 F1 · derivative.exercise_date: Vests annually over three years in increments of one-third each year, commencing on February 18, 2023. Read SEC document
May 01, 2021 Filed May 3, 2021 20:41 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionRestricted Stock Units · Derivative	515	$0.00	$0.00	Disclosure SEC source: 0001062993-21-004047 · form4.xml · derivative · entry 3 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 515 Underlying: Common Stock · 515 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: 515 of the RSUs vested on May 1, 2021. The remaining 515 RSUs will vest on May 1, 2022. F3 · derivative.expiration_date: 515 of the RSUs vested on May 1, 2021. The remaining 515 RSUs will vest on May 1, 2022. Read SEC document
May 01, 2021 Filed May 3, 2021 20:41 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Tax withholdingCommon Stock	162	$177.27	$28,717.74	Disclosure SEC source: 0001062993-21-004047 · form4.xml · nonDerivative · entry 2 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,098 F1 · shares: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Read SEC document
May 01, 2021 Filed May 3, 2021 20:41 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionCommon Stock	515	$0.00	$0.00	Disclosure SEC source: 0001062993-21-004047 · form4.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 12, 2021 Filed Apr 15, 2021 01:36 UTC	BIOLIFE SOLUTIONS INC BLFS · Entity 4614	GrantCommon Stock	5,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-21-008947 · rdgdoc.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The restricted stock award was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and fully vests on the first anniversary of the grant date. Read SEC document
February 26, 2021 Filed Mar 2, 2021 23:35 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionRestricted Stock Units · Derivative	156	$0.00	$0.00	Disclosure SEC source: 0001062993-21-002183 · form4.xml · derivative · entry 3 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 156 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: Earned RSUs vested on February 26, 2021. F3 · derivative.expiration_date: Earned RSUs vested on February 26, 2021. Read SEC document
February 26, 2021 Filed Mar 2, 2021 23:35 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Tax withholdingCommon Stock	58	$163.92	$9,507.36	Disclosure SEC source: 0001062993-21-002183 · form4.xml · nonDerivative · entry 2 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,745 F1 · shares: Represents shares withheld by Zimmer Biomet Holdings, Inc. (the "Company") to satisfy tax withholding obligations on the vesting of restricted stock units ("RSUs"). Read SEC document
February 26, 2021 Filed Mar 2, 2021 23:35 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	Exercise / conversionCommon Stock	156	$0.00	$0.00	Disclosure SEC source: 0001062993-21-002183 · form4.xml · nonDerivative · entry 1 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 25, 2021 Filed Mar 1, 2021 21:53 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	GrantEmployee Stock Option (right to buy) · Derivative	8,479	$0.00 Strike: $163.79	$0.00	Disclosure SEC source: 0001062993-21-002090 · form4.xml · derivative · entry 1 Ellingson Rachel · CIK 0001557271 · SVP & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,479 Underlying: Common Stock · 8,479 shares Expires 2031-02-25 F1 · derivative.exercise_date: Vests annually over four years in increments of 25% each year, commencing on February 25, 2022. Read SEC document
February 18, 2021 Filed Feb 22, 2021 22:04 UTC	ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278	GrantRestricted Stock Units · Derivative	156	$0.00	$0.00	Disclosure SEC source: 0001062993-21-001858 · form4.xml · derivative · entry 1 Ellingson Rachel · CIK 0001557271 · SVP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156 Underlying: Common Stock · 156 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock. F2 · shares: On February 26, 2019, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2019 - 2021, with an opportunity for interim payouts after 2019 and 2020 depending on actual performance. As determined on February 18, 2021, based on actual performance for 2020, the reporting person earned 156 RSUs. F3 · derivative.exercise_date: Earned RSUs will vest on February 26, 2021. F3 · derivative.expiration_date: Earned RSUs will vest on February 26, 2021. F2 · derivative.underlying_shares: On February 26, 2019, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2019 - 2021, with an opportunity for interim payouts after 2019 and 2020 depending on actual performance. As determined on February 18, 2021, based on actual performance for 2020, the reporting person earned 156 RSUs. F2 · balance_after: On February 26, 2019, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2019 - 2021, with an opportunity for interim payouts after 2019 and 2020 depending on actual performance. As determined on February 18, 2021, based on actual performance for 2020, the reporting person earned 156 RSUs. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:13 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerRestricted Stock Units · Derivative	2,028	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-000588 · edgar.xml · derivative · entry 9 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,028 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:13 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerStock Options (Right to Buy) · Derivative	25,464	Not disclosed Strike: $61.62	Not disclosed	Disclosure SEC source: 0001179110-17-000588 · edgar.xml · derivative · entry 8 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,464 shares Expires 2023-12-07 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:13 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerRestricted Stock Units · Derivative	1,114	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-000588 · edgar.xml · derivative · entry 7 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,114 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:13 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerStock Options (Right to Buy) · Derivative	19,616	Not disclosed Strike: $69.08	Not disclosed	Disclosure SEC source: 0001179110-17-000588 · edgar.xml · derivative · entry 6 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,616 shares Expires 2022-12-08 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:13 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerRestricted Stock Units · Derivative	401	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-000588 · edgar.xml · derivative · entry 5 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 401 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:13 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerStock Options (Right to Buy) · Derivative	13,380	Not disclosed Strike: $59.41	Not disclosed	Disclosure SEC source: 0001179110-17-000588 · edgar.xml · derivative · entry 4 Ellingson Rachel · CIK 0001557271 · VP, Global Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,380 shares Expires 2021-12-10 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.